PROCEPT BioRobotics Corp Quarterly Report Released - Here’s What You Should Know

PROCEPT BioRobotics Corporation – Q3 2025 Investor Summary

Financial Performance

• Revenue for Q3 2025 was $83.3 million, a 43% increase from $58.4 million in Q3 2024. Year-to-date (nine months ended September 30, 2025) revenue was $231.7 million, up 48% from $156.3 million in the prior-year period.
  • Key drivers: U.S. revenue ($203.8M YTD, up from $140.1M) and strong growth in handpieces/consumables ($141.5M YTD, up 60% year-over-year).
• Gross margin improved to 65% in Q3 2025 (from 63% in Q3 2024), and 65% YTD 2025 (up from 60%).
• Net loss for Q3 2025 was $21.4 million ($0.38 per share, basic/diluted), compared to $21.0 million ($0.40) in Q3 2024. Net loss YTD was $65.7 million ($1.19 per share), an improvement from $72.6 million ($1.41) YTD 2024.
• Operating expenses rose 30% year-over-year for the quarter, driven mainly by selling, general, and administrative costs (+38% to $59.0M in Q3) and R&D spending (+9% to $18.2M).
• Operating cash flow was negative $38.7 million YTD 2025, significantly improved from negative $66.8 million YTD 2024.
• Cash and cash equivalents at September 30, 2025 stood at $294.3 million (down from $333.7 million at year-end 2024). No preferred stock outstanding.
• Accumulated deficit increased to $611.7 million (from $546.0 million at year-end 2024).
• Long-term debt was $51.6 million, related to a term loan facility maturing in October 2027.

Operational & Balance Sheet Highlights

• Installed base: 835 robotic systems globally as of September 30, 2025.
• Inventory increased to $66.7 million (from $56.2 million at December 31, 2024); property and equipment, net, also increased to $30.0 million.
• Accounts receivable rose slightly to $84.5 million (from $83.5 million).
• Active investments in product innovation and commercial expansion, as shown by increased R&D and SG&A.
• Stock-based compensation expense was $36.8 million YTD 2025 vs. $22.8 million in the prior-year period.

Key Risks

• Loss-making with a significant accumulated deficit; the company anticipates continued net losses as it invests in growth and innovation.
• Heavy reliance on continued growth in robotic system installations and procedure volumes for future profitability.
• The term loan requires maintaining at least $100 million in available cash; falling below requires the company to establish and maintain additional cash collateral.
• Potential future risks include product recalls, regulatory actions, litigation, delays or failures in clinical development, competitive pressures, and possible reimbursement changes.
• No customer accounts for >10% of revenue or receivables, reducing customer concentration risk.
• The company has sufficient liquidity for at least the next twelve months based on current plans.

Legal and Regulatory

• No pending legal proceedings with material impact as of the filing date.
• No new material risks identified during the quarter beyond those previously disclosed.
• Continued focus on regulatory compliance and defending/enforcing intellectual property.

Overall Assessment

PROCEPT BioRobotics continues to show strong revenue growth and improving gross margins, driven by increased adoption and utilization of its Aquablation system. Despite ongoing net losses and a growing accumulated deficit, increased operating scale and a reduced cash burn rate underscore progress toward operating leverage. Cash reserves remain ample relative to near-term needs, but ongoing R&D, commercialization costs, and required term loan covenants warrant investor attention. The company is well-positioned in its market but remains subject to execution, regulatory, and industry reimbursement risks.

Visit Publicview AI to search and analyze millions of SEC filings using AI.